Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥509,484 | ¥685,327 | ¥631,945 | ¥421,489 |
| - Cash | ¥77,161 | ¥89,210 | ¥79,951 | ¥72,791 |
| + Debt | ¥50,223 | ¥10,494 | ¥11,693 | ¥21,383 |
| Enterprise Value | ¥482,546 | ¥606,611 | ¥563,687 | ¥370,081 |
| Revenue | ¥308,625 | ¥270,840 | ¥238,664 | ¥199,646 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Gross Profit | ¥169,381 | ¥157,286 | ¥137,421 | ¥116,489 |
| % Margin | 54.9% | 58.1% | 57.6% | 58.3% |
| EBITDA | ¥56,424 | ¥50,403 | ¥42,338 | ¥35,810 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |
| Net Income | ¥31,005 | ¥30,936 | ¥26,377 | ¥21,127 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS Diluted | 135.46 | 135.21 | 115.29 | 92.34 |
| % Growth | 0.2% | 17.3% | 24.9% | – |
| Operating Cash Flow | ¥36,917 | ¥34,245 | ¥30,924 | ¥27,250 |
| Capital Expenditures | -¥9,080 | -¥8,912 | -¥9,908 | -¥11,328 |
| Free Cash Flow | ¥27,837 | ¥25,333 | ¥21,016 | ¥15,922 |